Barnabas Desta

Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States

Irene B. Murimi, Dora H. Lin, Hong Kan et al. · The Journal of Rheumatology · 2020 · 64 citations · Full text

Pharmacy, Internal Medicine, Pharmacoeconomics +17

The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization

Andreas Schwarting, Heiko Friedel, Elena Garal‐Pantaler et al. · Rheumatology and Therapy · 2021 · 45 citations · Full text

Medicine, German, Clinical Epidemiology +16

Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols.

J. Longmore, Hargreaves Rj, Chantal M. Boulanger et al. · PubMed · 1997 · 42 citations

Medicine, Cardiology, Pharmacology +15

5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519

J. Longmore, Chantal M. Boulanger, Barnabas Desta et al. · British Journal of Clinical Pharmacology · 1996 · 41 citations · Full text

Medicine, Cardiology, Pharmacology +15

Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015

Edward R. Hammond, Barnabas Desta, Aimee M. Near et al. · Lupus Science & Medicine · 2021 · 37 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +12